3.1. The primary endpoint and risk of MODS
MODS
MODS, MULTIPLE ORGAN DYSFUNCTION SYNDROME, UTI
After treatment, the total 30-day mortality was 16.74% (40/239), according to the findings. The 30-day mortality was 15.38% (14/120) in the UTI group and 28.89% (26/119) in the placebo control group. As opposed to the UTI group, the placebo group exhibited a remarkably greater 30-day mortality rate, with a significant difference (Comparison of 7-day mortality and clinical efficacy.MODS = multiple organ dysfunction syndrome, UTI = ulinastatin.